The Postmenopausal Vaginal Atrophy Treatment & Drug Market size is estimated to reach $4.3 billion by 2030, growing at a CAGR of 7.3% during the forecast period 2023-2030. The growth of the Postmenopausal Vaginal Atrophy Treatment & Drug Market is greatly fueled by the increasing predominance of postmenopausal vaginal atrophy and the launch of advantageous healthcare plans in countries like the U.S. Based on Therapy Type, the Postmenopausal Vaginal Atrophy Drugs Market is segmented into Estrogen-based Drugs and Non-estrogen-based Drugs. 

According to IndustryARC’s analysis, North America has emerged as the most profitable region in the market. In 2022, the North American region held a 40% share of the total revenue earned by the market globally. The growth was driven by the soaring awareness regarding accessible treatment alternatives like estrogen-based drugs for the treatment of postmenopausal vaginal therapy among women in the North American region.

For More Queries About "Postmenopausal Vaginal Atrophy Treatment & Drug Market" @ https://www.industryarc.com/support.php?id=17539

Postmenopausal Vaginal Atrophy Treatment & Drug Market Growth Drivers:

  • Surging Applications of Therapies for the Treatment of Postmenopausal Problems:

Estrogen-based drugs and non-estrogen-based drugs are accessible for the treatment of postmenopausal vaginal therapy. Vulvovaginal atrophy (VVA) is a quiet epidemic that influences up to 50%-60% of postmenopausal women. Pharmaceutical preparations with estrogen for topical application are accessible in the form of a cream, tablets and a vaginal estrogen-releasing ring which may include estriol, conjugated equine estrogens, estradiol or estrone. More women are requesting non-hormonal treatments including non-estrogen-based drugs for menopausal symptoms. The surging applications of therapies for the treatment of postmenopausal vaginal therapy are therefore driving the growth of the Postmenopausal Vaginal Atrophy Treatment & Drug Market.

  • Increasing Investigations Pertaining to Vaginal Gels for Treatment of Postmenopausal Vaginal Atrophy:

About 90% of postmenopausal women are enduring vaginal atrophy. Investigations pertaining to vaginal gels like oxytocin vaginal gel have been performed to assess the impact of oxytocin vaginal gel on vaginal atrophy among postmenopausal women. The outcomes of the investigations demonstrated that an eight-week intervention with oxytocin vaginal gel (400 IU) could considerably enhance the vaginal maturation index. The growing investigations pertaining to vaginal gels for the treatment of postmenopausal vaginal atrophy are therefore propelling the growth of the Postmenopausal Vaginal Atrophy Treatment & Drug Industry. This is contributing to the Postmenopausal Vaginal Atrophy Treatment & Drug Industry Outlook.

Product Launch

In January 2022, Novo Nordisk India introduced a first-of-its-kind diabetes treatment medicine. The firm pronounced that it has launched the world's earliest and only oral semaglutide. This is the first time that the medicine has been developed in an oral form.

Postmenopausal Vaginal Atrophy Treatment & Drug Market: Competitive Landscape

Key companies holding major shares in the Postmenopausal Vaginal Atrophy Treatment & Drug Market are EndoCeutics, Upsher-Smith Laboratories, TherapeuticsMD, Bionovo, Pfizer Inc., Novo Nordisk A/S, Allergan plc, Shionogi & Co., Ltd., Ligand Pharmaceuticals Incorporated and Bayer AG.

To request for a quote, provide your details in the below link:

Media Contact:

Mr. Venkat Reddy
Sales Manager
Contact Sales: +1-970-236-3677

About IndustryARC: IndustryARC is a Research and Consulting Firm that publishes more than 500 reports annually, in various industries such as Agriculture, Automotive, Automation & Instrumentation, Chemicals and Materials, Energy and Power, Electronics, Food and Beverages, Information Technology, and Life sciences and Healthcare.